Please login to the form below

Not currently logged in
Email:
Password:

Radical NHS Health Reforms 

A panel of NHS experts discussed the NHS health reforms during a live webinar on August 9, 2010

Topics discussed:
Will these changes free the NHS to deliver improved services for patients, or is it a recipe for anarchy which will lead to an explosion of private healthcare provision?
These proposals recently announced by Health Secretary, Andrew Lansley are already polarising opinion. At the moment there are far more questions than answers, so PMGroup have brought together a number of experts to discuss the implications of these proposals, and to discuss the questions that are at the front of your minds.


The expert panel includes

  • Michael Sobanja, chief executive, NHS Alliance
  • Mark Wilkinson, director of life sciences innovation for the NHS and former PCT chief executive
  • Tim Jones, commissioning specialist, and adviser to a number of Primary Care Trusts and Practice Based Commissioning Groups
  • Ray Rowden, health policy analyst and former special adviser to the House of Commons Health committee
  • Nick Goodwin, senior fellow, Kings Fund (chair).

A BrightTALK Channel

Featured jobs

Senior Brand Manager - Harlow
Competitive
Sales Manager - Media Publishing – Cheshire
25,000 to 35,000 per annum
UK Marketing Director
80,000 to 100,000 per annum
Group Account Director –Healthcare Advertising
Neg

Subscribe to our email news alerts

PMHub

Add my company
grey healthcare group - London

Brand building has been transformed by more than a decade of digital communications. The traditional models for information flow, from ...

Latest intelligence

Clinical trial regulation in Mexico
Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing...
Online Physician Communities
How can pharma deliver returns on increased digital investment?
Independent online professional networks work best as part of a multi-channel campaign  ...
The impact of Hollande's healthcare reforms in France
A tougher environment for pharma, with market access and regulatory challenges...